Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma

Bruton tyrosine kinase (BTK) inhibitor ibrutinib has been validated as an effective drug to treat B cell malignancies. Combined therapies comprising ibrutinib and anti-CD20 antibodies like rituximab were designed as a backbone in many clinical trials. However, the off-target inhibition of ibrutinib...

Full description

Bibliographic Details
Main Authors:	Hui Yu, Xing Wang, Jiao Li, Yingying Ye, Dedao Wang, Wei Fang, Lan Mi, Ning Ding, Xiaogan Wang, Yuqin Song, Jun Zhu
Format:	Article
Language:	English
Published:	Elsevier 2021-06-01
Series:	Molecular Therapy: Oncolytics
Subjects:	anti-CD20 antibody BTK inhibitor B cell lymphoma combined effects
Online Access:	http://www.sciencedirect.com/science/article/pii/S2372770521000498

Similar Items

Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines
by: Ryohei Kozaki, et al.
Published: (2018-04-01)

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
by: Yizi He, et al.
Published: (2019-02-01)

Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment
by: Letizia Polito, et al.
Published: (2013-10-01)

Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab
by: Gianpaolo Marcacci, et al.
Published: (2021-06-01)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
by: Lauren E. Kueffer, et al.
Published: (2021-06-01)

The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma
by: K D Kaplanov, et al.
Published: (2014-06-01)

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
by: Alexandra Albertsson-Lindblad, et al.
Published: (2019-08-01)

p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
by: Federica Giordano, et al.
Published: (2019-06-01)

An update on newer monoclonal antibodies in lymphoma therapy
by: Subhashini Archana Kadavakolan, et al.
Published: (2016-01-01)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
by: Ma B, et al.
Published: (2017-04-01)

Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
by: Datong Zhang, et al.
Published: (2021-08-01)

Loss of CD20 Expression in Follicular Lymphoma after Program Anti-Tumor Therapy Including Rituximab: Literature Data and Case Report
by: OM Volodina, et al.
Published: (2017-04-01)

Biodistribution and Anti-tumor Activities of the 131I-labeled Rituximab in Nude Mice Bearing Human Burkitt’s lymphoma
by: Qiang ZUO, et al.
Published: (2009-08-01)

Abivertinib synergistically strengthens the anti‐leukemia activity of venetoclax in acute myeloid leukemia in a BTK‐dependent manner
by: Shujuan Huang, et al.
Published: (2020-10-01)

Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
by: Song L, et al.
Published: (2019-02-01)

Emerging therapies in mantle cell lymphoma
by: Walter Hanel, et al.
Published: (2020-06-01)

CD20+ cutaneous T-cell lymphoma with phenotypic shift after treatment with rituximab: Case report and review of the literature
by: Amanda J. Tschetter, MD, et al.
Published: (2020-04-01)

Targeting Solid Tumors With BTK Inhibitors
by: Fatih M. Uckun, et al.
Published: (2021-04-01)

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
by: Rula Zain, et al.
Published: (2021-07-01)

Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
by: Chiara Brullo, et al.
Published: (2021-07-01)

Clinical characteristics and prenatal diagnosis for 22 families in Henan Province of China with X-linked agammaglobulinemia (XLA) related to Bruton’s tyrosine kinase (BTK) gene mutations
by: Shanshan Gao, et al.
Published: (2020-06-01)

Novel applications of Rituximab in dermatological disorders
by: Prasan R Bhandari, et al.
Published: (2014-01-01)

Application of monoclonal anti-CD20 antibody rituximab in the treatment of non-Hodgkin's lymphoma
by: Mihaljević Biljana, et al.
Published: (2008-01-01)

Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway
by: C. I. Edvard Smith, et al.
Published: (2021-06-01)

Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant
by: Camille Libre, et al.
Published: (2020-04-01)

Immunotherapy for B-cell lymphoma: current status and prospective advances
by: Nurit eHollander
Published: (2012-01-01)

Pemphigus: Current and Future Therapeutic Strategies
by: Dario Didona, et al.
Published: (2019-06-01)

Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma
by: Haifeng Zhang, et al.
Published: (2013-09-01)

Production and Characterization of New Anti-Human CD20 Monoclonal Antibody
by: Mahdi Fasihi-Ramandi, et al.
Published: (2015-10-01)

Immunoaffinity isolation of Btk´s signalosome, a proteomic approach to identifying interacting proteins
by: Herron, John Paul
Published: (2006)

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence
by: Masoud Etemadifar, et al.
Published: (2017-01-01)

Estudo do gene btk (bruton\'s tyrosine quinase) em pacientes com agamaglobulinemia congênita
by: Oliveira, Rosana Rezende de
Published: (2008)

Estudo do gene btk (bruton\'s tyrosine quinase) em pacientes com agamaglobulinemia congênita
by: Rosana Rezende de Oliveira
Published: (2008)

BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
by: Marzia Palma, et al.
Published: (2021-07-01)

Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review
by: Jessica D. Rich, et al.
Published: (2019-10-01)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
by: Sining Zhu, et al.
Published: (2021-08-01)

Effect of host plant on gypsy moth diet and biological efficacy of Btk preparations
by: Milanović Slobodan, et al.
Published: (2006-01-01)

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
by: Naoki Wada, et al.
Published: (2009-10-01)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
by: Zhu Z, et al.
Published: (2020-05-01)

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma
by: Emil Aagaard Thomsen, et al.
Published: (2020-09-01)